Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects.

Overview

PE-22-28 is a synthetic heptapeptide corresponding to residues 22–28 of spadin, a naturally occurring 16-amino acid propeptide cleaved from the neurotensin receptor 3 (NTSR3/sortilin) protein. Spadin was identified through a landmark discovery by researchers at the Institute of Molecular and Cellular Pharmacology (IPMC) in France, who demonstrated that the TREK-1 background potassium channel (TWIK-Related K+ channel 1) is a critical mediator of SSRI resistance and that its blockade produces rapid antidepressant effects. TREK-1 knockout mice display a depression-resistant phenotype mimicking the effects of chronic SSRI treatment, and spadin was identified as an endogenous TREK-1 blocker. PE-22-28 was subsequently developed as the minimal active fragment of spadin, retaining full TREK-1 blocking activity with improved pharmacological properties.

TREK-1 is a two-pore domain potassium (K2P) channel highly expressed in the hippocampus, prefrontal cortex, amygdala, and hypothalamus — brain regions centrally involved in mood regulation and stress response. Under basal conditions, TREK-1 generates a background "leak" potassium current that hyperpolarizes neuronal membranes and reduces excitability. By blocking TREK-1, PE-22-28 increases neuronal excitability in serotonergic neurons of the dorsal raphe nucleus, enhancing serotonin release and downstream signaling. Critically, this mechanism produces antidepressant effects within 4 days of treatment in rodent models (forced swim test, novelty-suppressed feeding, splash test) — dramatically faster than the 2–4 week onset of conventional SSRIs, which require gradual desensitization of 5-HT1A autoreceptors. Additionally, PE-22-28 stimulates hippocampal neurogenesis, increases BDNF expression, and enhances synaptic plasticity through mechanisms downstream of TREK-1 blockade and potentially overlapping with the effects of P21 and Semax.

PE-22-28 is administered via intraperitoneal injection in preclinical studies, typically at doses of 0.1–1 mg/kg, and has been explored intranasally and subcutaneously in research contexts. Human clinical data is not yet available, and the compound remains at the investigational stage. In nootropic and research communities, PE-22-28 is of interest for combination with serotonergic modulators such as 5-HTP and with neuroplasticity enhancers like lion's mane and NA-Semax Amidate. The unique mechanism targeting an ion channel upstream of monoamine release distinguishes PE-22-28 from both conventional antidepressants and ketamine-like rapid-acting agents, potentially offering a novel therapeutic pathway for treatment-resistant depression with fewer side effects than NMDA receptor modulation.

Mechanism of Action

Mechanism of Action

PE-22-28 is a synthetic heptapeptide optimized from spadin, a natural peptide derived from the maturation of sortilin (NTSR3). It represents a novel class of antidepressant that targets TREK-1 potassium channels rather than monoamine transporters.

TREK-1 Channel Inhibition

TREK-1 (K2P2.1) is a two-pore domain potassium channel that generates background leak currents maintaining neuronal resting membrane potential. PE-22-28 blocks TREK-1 with exceptional potency (IC50 ~0.12 nM), approximately 1000-fold more potent than spadin. This blockade reduces potassium efflux, depolarizing the resting membrane potential of TREK-1-expressing neurons and bringing them closer to firing threshold.

Dorsal Raphe Serotonin Neurons

TREK-1 is highly expressed in serotonergic neurons of the dorsal raphe nucleus, where it serves as a key regulator of neuronal excitability. TREK-1 knockout mice display a depression-resistant phenotype, validating this channel as an antidepressant target. PE-22-28 blockade of TREK-1 increases the spontaneous firing rate of these neurons, enhancing serotonin release across widespread forebrain projection areas.

Downstream Signaling Cascade

Elevated serotonin activates postsynaptic 5-HT4 and 5-HT1A receptors in the hippocampus, triggering cAMP/PKA signaling and CREB phosphorylation. Activated CREB drives transcription of BDNF, which supports dendritic remodeling, spine formation, and new synapse stabilization. This plasticity-promoting cascade is believed to underlie the sustained antidepressant effects.

Neurogenesis

PE-22-28 increases hippocampal neurogenesis through the CREB/BDNF pathway. Increased neurogenesis in the dentate gyrus is increasingly recognized as a required component of the antidepressant response, and PE-22-28's neurogenic effect develops within 4 days of treatment in animal models, faster than conventional SSRIs.

Reconstitution Calculator

Safety Profile

Safety Profile: PE-22-28

Common Side Effects

• Limited human safety data available; most information derived from preclinical research
• Headache and mild cognitive overstimulation reported anecdotally
• Nasal irritation when administered intranasally
• Mild anxiety or restlessness at higher doses
• Insomnia if taken late in the day

Serious Adverse Effects

• No controlled human clinical trials have been conducted; serious adverse effect profile is unknown
• Theoretical risk of excessive BDNF pathway modulation
• Potential neurotoxicity at supratherapeutic doses (extrapolated from animal studies)
• Unknown long-term safety profile for chronic use
• Risk of contamination or mislabeling from unregulated peptide suppliers

Contraindications

• Pregnancy and breastfeeding (no safety data available)
• Children and adolescents under 18 years
• History of seizure disorders (BDNF modulation may lower seizure threshold)
• Active neuropsychiatric conditions without physician supervision
• Known hypersensitivity to PE-22-28 or related peptides

Drug Interactions

• Antidepressants (SSRIs, SNRIs): Theoretical additive effects on BDNF pathways; monitor for serotonergic effects
• Antiepileptic drugs: May counteract seizure threshold effects; use with extreme caution
• Other nootropic peptides (Semax, Selank, Dihexa): Potential additive neurotrophic effects; avoid stacking without medical guidance
• CNS stimulants: May increase risk of overstimulation, anxiety, and insomnia

Population-Specific Considerations

• Cognitive enhancement seekers: Primary user demographic; typical intranasal doses range from 50-200 mcg; start low
• Researchers: PE-22-28 is derived from the PACAP peptide and acts as a partial agonist; intended for research use
• Critical safety note: PE-22-28 has no regulatory approval for human use in any jurisdiction. No human clinical trials have been published. All safety information is extrapolated from animal research and anecdotal user reports. Users assume full responsibility for unknown risks.

Pharmacokinetic Profile